HIGHLIGHTS
- who: Sandi Kwee and Xin Chen from the University of Hawaii Cancer Center, Honolulu, Hawaii, HI, USA have published the paper: Immunotherapy biomarkers for HCC: contemporary challenges and emerging opportunities, in the Journal: (JOURNAL) of 10/08/2022
- future: While compelling as a suggestion that MRI is a potential source of immunotherapy biomarkers for HCC additional independent cohort studies will be needed to substantiate these results.
SUMMARY
The CheckMate-040 multi-cohort trial first demonstrated the effectiveness of an anti-PD1 antibody (nivolumab) in patients with clinically advanced HCC previously treated . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.